secwatch.observer — SEC 8-K summary
======================================

Issuer:     NEKTAR THERAPEUTICS (NKTR)
CIK:        0000906709
Form:       8-K
Filed at:   2025-11-06T23:59:59+00:00
Accession:  0001213900-25-107180
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Nektar Q3 net loss $35.5M ($1.87/sh), revenue $11.8M; cash $270.2M; rezpeg data at ACAAI
--------------------------------------------------------------------------------

- Net loss $35.5M ($1.87/sh) vs $37.1M ($2.66/sh) in Q3 2024.
- Revenue $11.8M, down from $24.1M YoY due to sale of Huntsville facility in Dec 2024.
- Cash & marketable securities $270.2M as of Sep 30, 2025; includes $107.2M from July secondary offering.
- R&D expense $27.3M vs $35.0M YoY; focus on rezpegaldesleukin, NKTR-0165, NKTR-422.
- FDA granted Fast Track for rezpegaldesleukin in severe alopecia areata; topline data expected Dec 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/906709/000121390025107180/0001213900-25-107180-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/906709/000121390025107180/ea0264261-8k_nektar.htm
  HTML page:      https://secwatch.observer/filing/0001213900-25-107180

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer